206. Fragile X syndrome Clinical trials / Disease details
Clinical trials : 104 / Drugs : 87 - (DrugBank : 32) / Drug target genes : 54 - Drug target pathways : 79
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01329770 (ClinicalTrials.gov) | December 2010 | 29/3/2011 | Safety and Efficacy Study of Antioxidants for the Treatment of the Fragile X Syndrome | Phase II Double-blind Randomized Placebo-controlled 1-way Crossover Trial to Investigate Safety and Efficacy of the Ascorbic Acid and Tocopherol for the Treatment of the Fragile X Syndrome | Fragile X Syndrome | Dietary Supplement: Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E);Dietary Supplement: Placebo | Yolanda de Diego Otero | NULL | Completed | 6 Years | 18 Years | Male | 30 | Phase 2 | Spain |